Home > Boards > US OTC > Medical - Drugs > Relief Therapeutics Holding AG (RLFTF)

Relief & NeuroRX Leadership (Brief Summary)

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Uncle Gee Gee Member Profile
 
Followed By 22
Posts 635
Boards Moderated 0
Alias Born 08/19/20
160x600 placeholder
NRx Pharma jumps 36% on positive aviptadil data in Critical COVID-19 Seeking Alpha - 10/14/2021 7:12:57 AM
NRx Pharma issues update on global development of Zyesami Seeking Alpha - 10/12/2021 7:21:00 AM
Acer Therapeutics nabs new U.S. patents for ACER-001 formulation Seeking Alpha - 10/7/2021 8:48:51 AM
NRx Pharma's Zyesami improves survival in highly comorbid COVID-19 patients Seeking Alpha - 9/27/2021 8:12:56 AM
NRx Pharma jumps 10% after Zyesami shows relief from respiratory distress due to COVID-19 Seeking Alpha - 8/30/2021 8:28:16 AM
NRx Pharma jumps 16% on Zyesami distribution deal with Cardinal Health Seeking Alpha - 8/26/2021 8:16:02 AM
Relief Therapeutics' RLF-100 secures Orphan Drug tag in U.S. Seeking Alpha - 8/3/2021 1:36:33 AM
NRx Pharma stock soars 24% on commercial formulation for Zyesami Seeking Alpha - 7/22/2021 7:26:09 AM
NRx Pharma shares jump 12% as Zyesami helps prevent cytokine storm in COVID-19 Seeking Alpha - 7/19/2021 7:10:31 AM
IQST ALERT - PPS Breaks 20 Day MA Gaining Electric Vehicle Momentum In Wake Of ALYI Breakout InvestorsHub NewsWire - 6/17/2021 11:28:13 AM
New operating chief at Relief Therapeutics Seeking Alpha - 5/28/2021 2:23:09 AM
Acer Therapeutics plans NDA submission for ACER-001 in Q3 2021 Seeking Alpha - 5/25/2021 8:48:36 AM
Relief updates on progress of ACER-001 for urea cycle disorders Seeking Alpha - 5/18/2021 4:41:50 AM
Relief inks binding term sheet to acquire outstanding shares of APR Applied Pharma Seeking Alpha - 5/4/2021 2:02:09 AM
Relief initiates Phase 2 trial with inhaled RLF-100 in COVID-19-related ARDS Seeking Alpha - 4/22/2021 2:18:03 AM
Nightfood, Inc. (OTCQB: NGTF) in Walmart (NYSE: WMT) Coast to Coast over 1,000 Locations InvestorsHub NewsWire - 4/20/2021 7:09:50 AM
Relief Therapeutics reports FY2020 results, provides pipeline update Seeking Alpha - 4/15/2021 1:40:24 AM
Relief Therapeutics' Zyesami shows meaningful benefit in survival and recovery from COVID-19 Seeking Alpha - 3/29/2021 1:39:29 AM
Relief Therapeutics raises CHF10M capital via private placement Seeking Alpha - 3/12/2021 5:18:55 AM
Relief Therapeutics' RLF-100 can reduce hospital stay due to COVID-19 Seeking Alpha - 2/10/2021 6:49:43 AM
Relief initiates phase 2/3 trial of inhaled RLF-100 in severe COVID-19 Seeking Alpha - 2/8/2021 1:51:43 AM
Companies on the Frontline, Helping Us Through the Pandemic InvestorsHub NewsWire - 11/30/2020 8:35:00 AM
Uncle Gee Gee   Thursday, 09/10/20 08:16:07 AM
Re: None
Post # of 42891 
Relief & NeuroRX Leadership (Brief Summary)

Here are a few highlights about a few of the leaders at Relief & NeuroRX. Each of these individuals bring with them impressive educational backgrounds, extensive world-class experience, and connections into the highest levels of government and some of the largest companies in the United States. These individuals, along with other equally-impressive team members, are leading RLF-100 through the FDA process and preparing for launch.

Dr. Jonathan Javitt – NeuroRX Founder, CEO, and Chairman of the Board
• Dr Javitt is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School.
• He was appointed to healthcare leadership roles under Presidents Reagan, Bush Sr, Clinton, and Bush Jr.
• Dr. Javitt led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer.
• He held leadership roles in seven successful healthcare IT and biopharma startups with public exits.
• He previously served as expert consultant to the World Bank, the National Institutes of Health, the Health Care Financing Administration, Department of Veterans Affairs, and the ministries of health of United Kingdom, Sweden, Australia, Japan, and the Netherlands.

Dr. Ram (Raghuram Selvaraju) – Relief Chairman of the Board
• Holds a BS in Molecular Biology, a MS in Biological Sciences, a MS in Molecular Biology, a Ph.D. in Cellular Immunology and Molecular Neuroscience and an MBA from Cornell University, Carnegie Mellon University, and University of Geneva.
• Dr. Ram has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV, and is widely quoted in national publications such as Barron’s and The Wall Street Journal, The Pink Sheet, BioWorld Today, and BioCentury.
• He was formally the Vice President in Equity Research, Managing Director, and Senior Analyst for multiple companies throughout his career.

Robert Besthof – NeuroRX Chief of Operations
• Mr. Besthof is a global biopharmaceutical executive who has spent his career at Eli Lilly & Pfizer.
• At Pfizer, he was head of the entire neuro science and pain division and was responsible for $10b of drugs.

Wayne Pines – NeuroRX Regulatory & Patient Advocacy Adviser
• Previously served as FDA Associate Commissioner.
• Was recently in the news as a long-term friend and advisor to Dr. Hahn (FDA Commissioner).

Peter Egon de Svastich – Relief Board Member
• Mr. de Svastich is a Managing General Partner of GEM.
• He holds a Business degree from Princeton, LLB/JD from Yale Law School, and LATF from Fletcher School of Law.
• He has been Principal Executive Officer, President, Principal Financial Officer, Treasurer and Secretary at Global Group Enterprises Corp.
• He has been the Chief Financial Officer, Chief Operating Officer, and Chief Compliance Officer for a number of hedge funds and funds of funds.
• Mr. de Svastich also served as a Partner, Chief Financial Officer, and Chief Compliance Officer of Alpha Equity Management.

Thomaz Burckhardt - Relief Board Member
• After completing his law studies, he held various positions in the areas of asset management and capital markets at leading international banks UBS, Deutsche Bank, JP Morgan, and Credit Suisse.
• He specializes in asset management, capital market transactions and mergers & acquisitions.


Disclaimer: I am not a professional advisor. Seek professional advice before investing or trading. I take risky positions and do not advise anyone to follow my opinions or actions.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences